Showing results (121-130 of 5,000) with videos related to
Sort By:
Pageof 500
American Journal of Clinical Oncology|May 10, 2011
Primary cutaneous anaplastic large-cell lymphomaEdward Perry, Jay Karajgikar, Imad A TabbaraAmerican Journal of Clinical Oncology|May 18, 2011
Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancerShaojun Lin, Ivan W K Tham, Jianji Pan, et al.American Journal of Clinical Oncology|May 18, 2011
Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening populationLuke E Pater, Kimberly W Hart, Brian J Blonigen, et al.American Journal of Clinical Oncology|May 25, 2011
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective reviewSeung Tae Kim, Jeeyun Lee, Se Hoon Park, et al.American Journal of Clinical Oncology|May 11, 2011
Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation studyLuciana Caravatta, Vincenzo Picardi, Rosa Tambaro, et al.American Journal of Clinical Oncology|May 11, 2011
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trialSteven R Alberts, Joel M Reid, Bruce W Morlan, et al.American Journal of Clinical Oncology|May 11, 2011
Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancerBao-Sheng Li, He-Yi Gong, Wei Huang, et al.American Journal of Clinical Oncology|May 4, 2011
Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapyJack Phan, Ali Mazloom, Mirna Abboud, et al.American Journal of Clinical Oncology|August 1, 1990
Low-dose total body irradiation in non-Hodgkin lymphoma: short- and long-term toxicity and prognostic factorW J De Neve, M L Lybeert, J H MeerwaldtAmerican Journal of Clinical Oncology|August 1, 1990
A phase II trial of carbetimer for the treatment of colorectal cancer. A trial of the Northern California Oncology GroupM W Audeh, C D Jacobs, T E Davis, et al.Pageof 500